A Study to Compare Efficacy and Safety of CT-P17 With Humira in Patients With Active Rheumatoid Arthritis

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2018
CT‐P17, containing the active ingredient adalimumab, is a recombinant humanized monoclonal antibody that is being developed as a similar biological medicinal product to Humira. The purpose of this study is to demonstrate similar efficacy and safety of CT‐P17 and Humira in patients with moderate to severe rheumatoid arthritis when co‐administered with methotrexate.
Epistemonikos ID: 8ba8ab5e1602c2c8692b28553559cd5a78a3d55d
First added on: Mar 23, 2022